Future directions in inflammatory bowel disease management

Letter: dry blood spots for anti-TNF treatment monitoring in IBD

(2013) N. Vande Casteele et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

Biosimilar monoclonal antibodies: a science-based regulatory challenge

(2013) Paul J Declerck   EXPERT OPINION ON BIOLOGICAL THERAPY

Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohnʼs Disease, and Ulcerative Colitis Patients

(2013) Scott Plevy et al.   INFLAMMATORY BOWEL DISEASES

Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota

(2013) Koji Atarashi et al.   NATURE

Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile

(2013) Els van Nood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations

(2013) Paul Chamberlain   Bioanalysis

Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease

(2012) J. L. Anderson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Food and the gut microbiota in inflammatory bowel diseases

(2012) Lindsey G. Albenberg et al.   CURRENT OPINION IN GASTROENTEROLOGY

How to Guide Therapeutic Decisions in a Patient-Tailored Approach to Treatment of IBD?

(2012) Paul Rutgeerts   DIGESTIVE DISEASES

Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease

(2012) Francesc Casellas et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease

(2012) Geert D'Haens et al.   GASTROENTEROLOGY

Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor α Agents for Inflammatory Bowel Disease

(2012) Shane M. Devlin et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Fecal Microbiota Transplantation

(2012) Thomas Julius Borody et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

TheNOD2insC polymorphism is associated with worse outcome following ileal pouch-anal anastomosis for ulcerative colitis

(2012) Andrea D Tyler et al.   GUT

Mucosal Healing in Crohnʼs Disease

(2012) Peter De Cruz et al.   INFLAMMATORY BOWEL DISEASES

The future of inflammatory bowel disease management: Combining progress in trial design with advances in targeted therapy

(2012) Simon Travis et al.   Journal of Crohns & Colitis

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

(2012) S. Schreiber et al.   Journal of Crohns & Colitis

Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease

(2012) Luke Jostins et al.   NATURE

Setting the stage for biosimilar monoclonal antibodies

(2012) Christian K Schneider et al.   NATURE BIOTECHNOLOGY

Interchangeability, immunogenicity and biosimilars

(2012) Hans C Ebbers et al.   NATURE BIOTECHNOLOGY

The advent of biosimilar therapies in rheumatology—“O Brave New World”

(2012) Morton A. Scheinberg et al.   Nature Reviews Rheumatology

A Glimpse of the Next 100 Years in Medicine

(2012) Isaac S. Kohane et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis

(2012) Renathe Rismo et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

(2011) L. S. Kiss et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

(2011) Matthias Jürgens et al.   Clinical Gastroenterology and Hepatology

Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?

(2011) Pal Miheller et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

(2011) Cosimo Prantera et al.   GASTROENTEROLOGY

Combination of genetic and quantitative serological immune markers are associated with complicated Crohnʼs disease behavior

(2011) Gary R. Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease

(2011) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Acceptable changes in quality attributes of glycosylated biopharmaceuticals

(2011) Martin Schiestl et al.   NATURE BIOTECHNOLOGY

Fecal microbiota transplantation and emerging applications

(2011) Thomas J. Borody et al.   Nature Reviews Gastroenterology & Hepatology

Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes

(2011) G. D. Wu et al.   SCIENCE

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

(2010) Waqqas Afif et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Disease Activity, ANCA and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

(2010) Matthias Jürgens et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Low-Dose Maintenance Therapy With Infliximab Prevents Postsurgical Recurrence of Crohn's Disease

(2010) Dario Sorrentino et al.   Clinical Gastroenterology and Hepatology

Genetic predictors of medically refractory ulcerative colitis

(2010) Talin Haritunians et al.   INFLAMMATORY BOWEL DISEASES

Predictive value of epithelial gene expression profiles for response to infliximab in Crohnʼs disease‡

(2010) Ingrid Arijs et al.   INFLAMMATORY BOWEL DISEASES

Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases

(2010) Daniel N. Frank et al.   INFLAMMATORY BOWEL DISEASES

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gene Expression Changes Associated with Resistance to Intravenous Corticosteroid Therapy in Children with Severe Ulcerative Colitis

(2010) Boyko Kabakchiev et al.   PLoS One

Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species

(2010) K. Atarashi et al.   SCIENCE

What is the optimal therapy for Crohn’s disease: step-up or top-down?

(2010) Ming Valerie Lin et al.   Expert Review of Gastroenterology & Hepatology

Genetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients

(2009) Liesbet Henckaerts et al.   Clinical Gastroenterology and Hepatology

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis

(2009) I. Arijs et al.   GUT

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease

(2009) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Importance of mucosal healing in ulcerative colitis

(2009) Gary R. Lichtenstein et al.   INFLAMMATORY BOWEL DISEASES

Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies

(2009) Klaus Bendtzen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment

(2009) Taina Sipponen et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Metagenomic Approaches for Defining the Pathogenesis of Inflammatory Bowel Diseases

(2008) Daniel A. Peterson et al.   Cell Host & Microbe

Microbial Influences in Inflammatory Bowel Diseases

(2008) R. Balfour Sartor   GASTROENTEROLOGY

Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection

(2008) Miguel Regueiro et al.   GASTROENTEROLOGY

Analysis of bacterial bowel communities of IBD patients: What has it revealed?

(2008) Harry Sokol et al.   INFLAMMATORY BOWEL DISEASES

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

(2008) H. Sokol et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA